Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 4.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,551 shares of the medical research company’s stock after selling 924 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Charles River Laboratories International were worth $3,654,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Nomura Asset Management Co. Ltd. lifted its position in shares of Charles River Laboratories International by 13.7% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 15,592 shares of the medical research company’s stock valued at $3,071,000 after buying an additional 1,882 shares in the last quarter. DF Dent & Co. Inc. raised its position in Charles River Laboratories International by 24.7% during the third quarter. DF Dent & Co. Inc. now owns 120,045 shares of the medical research company’s stock worth $23,645,000 after acquiring an additional 23,774 shares during the period. National Bank of Canada FI lifted its holdings in Charles River Laboratories International by 45.4% during the third quarter. National Bank of Canada FI now owns 21,216 shares of the medical research company’s stock valued at $4,179,000 after purchasing an additional 6,627 shares in the last quarter. iA Global Asset Management Inc. grew its position in shares of Charles River Laboratories International by 5,383.3% in the third quarter. iA Global Asset Management Inc. now owns 23,030 shares of the medical research company’s stock valued at $4,536,000 after purchasing an additional 22,610 shares during the period. Finally, EP Wealth Advisors LLC purchased a new stake in shares of Charles River Laboratories International during the third quarter worth about $273,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the topic of a number of research reports. Bank of America decreased their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday. Evercore ISI raised their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. Robert W. Baird dropped their price target on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a research report on Friday, September 20th. Redburn Atlantic started coverage on Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 price objective on the stock. Finally, UBS Group upped their target price on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $214.00.

Charles River Laboratories International Trading Down 2.0 %

Shares of CRL stock opened at $190.46 on Monday. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a twelve month low of $176.48 and a twelve month high of $275.00. The company’s 50-day moving average price is $194.35 and its 200-day moving average price is $202.96. The stock has a market cap of $9.74 billion, a price-to-earnings ratio of 23.84, a PEG ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same period in the previous year, the firm earned $2.72 earnings per share. Charles River Laboratories International’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).